US Patent

US9597289 — Liquid oral simvastatin compositions

Formulation · Assigned to Rosemont Pharmaceuticals Ltd · Expires 2030-02-23 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a liquid oral suspension formulation of simvastatin, the active ingredient in Zocor, with specific particle size requirements.

USPTO Abstract

A suspension which is suitable for oral administration, comprising simvastatin, at least one suspending agent, and at least one preservative, wherein at least 90 wt % of the particles of simvastatin are less than 100 Î¼m in diameter. The present invention also includes uses of the suspension and methods of making the suspension.

Drugs covered by this patent

Zocor (simvastatin) · Merck & Co.

Patent Metadata

Patent number: US9597289
Jurisdiction: US
Classification: Formulation
Expires: 2030-02-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Rosemont Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.